Optimizing Pulmonology Availity Integration for Prior Authorization

Achieving efficient **pulmonology Availity integration** is crucial for managing the complex prior authorization landscape of respiratory care, from specialty biologics to home oxygen therapies.

Revenue cycle leaders and prior authorization teams in pulmonology face significant administrative burdens. Navigating payer requirements for high-cost medications and durable medical equipment through platforms like Availity Essentials demands precision and speed to prevent care delays and revenue loss.

The Role of Availity Essentials in Pulmonology Prior Authorization

As a multi-payer clearinghouse, Availity Essentials serves as a primary channel for submitting prior authorization requests for a wide range of pulmonology services and medications. This platform centralizes interactions with numerous commercial payers, making efficient **pulmonology Availity integration** critical for streamlined operations within respiratory care practices.

Key Pulmonology Services Requiring Prior Authorization via Availity

  • Asthma biologics: omalizumab (Xolair), mepolizumab (Nucala), dupilumab (Dupixent), tezepelumab (Tezspire), and similar high-cost therapies.
  • COPD specialty drugs, including some triple-therapy inhalers like Trelegy and Breztri, often with step-therapy requirements.
  • IPF (idiopathic pulmonary fibrosis) antifibrotics such as pirfenidone (Esbriet) and nintedanib (Ofev).
  • Home oxygen, BiPAP, and CPAP equipment and services.
  • Pulmonary function testing and advanced diagnostic imaging.

Navigating Clinical Documentation for Pulmonology PAs

Pulmonology prior authorizations are heavily reliant on robust clinical documentation, often guided by standards from organizations like ATS, GOLD for COPD, and GINA for asthma. For biologics, specific data points like eosinophil counts, detailed exacerbation history, and evidence of prior controller therapy at maximum dose are frequently required by payers.

Klivira's Intelligent Automation for Pulmonology Availity Integration

Klivira automates the extraction and submission of critical clinical data, integrating directly with your EMR to populate Availity forms. Our platform incorporates GINA/GOLD/ATS-aware step-therapy logic and streamlines the collection of specific requirements, such as eosinophil counts, reducing manual effort and potential errors inherent in traditional workflows.

Benefits of Klivira for Pulmonology Prior Authorization Workflows

  • Automated data population from EMR to Availity for faster, more accurate submission.
  • Proactive identification of missing documentation based on payer policies and clinical guidelines.
  • Streamlined re-authorization workflows for chronic conditions like severe asthma requiring ongoing biologic therapy.
  • Reduced administrative burden on PA coordinators, allowing focus on complex clinical cases.
  • Improved adherence to payer-specific step-therapy requirements, mitigating common denial reasons.

EMR and Payer Touchpoints in the Integrated Workflow

An effective **pulmonology Availity integration** requires seamless data exchange between your EMR and the Availity platform. Klivira facilitates this by mapping clinical order types and diagnostic results from your EMR directly to the X12 278 transaction and payer portal fields within Availity, ensuring accurate and timely submissions without manual transcription.

Frequently asked questions

What specific pulmonology medications commonly require prior authorization through Availity?

High-cost asthma biologics like Dupixent, Nucala, Fasenra, and Tezspire frequently require PA. Additionally, certain COPD specialty drugs and IPF antifibrotics such as Ofev and Esbriet are often subject to prior authorization requirements due to their cost and specific clinical criteria.

How does Klivira address the documentation requirements for pulmonology PAs submitted via Availity?

Klivira automates the extraction of key clinical data, such as eosinophil counts and step-therapy history, directly from your EMR. This data is then used to pre-populate Availity forms or support documentation uploads, ensuring all necessary information is present according to payer and guideline requirements (e.g., GINA, GOLD, ATS).

What are common reasons for denial of pulmonology prior authorizations when using Availity?

Frequent denial reasons include failure to meet step-therapy requirements for asthma biologics, not reaching specific eosinophil-count thresholds for certain IL-5 targeting therapies, or insufficient documentation of conservative therapy trials for conditions like IPF. Klivira helps mitigate these by ensuring adherence to payer policies.

Can Klivira integrate with our EMR to streamline the Availity submission process for pulmonology?

Yes, Klivira integrates with leading EMR systems to pull relevant clinical data directly. This enables automated population of prior authorization requests within Availity, reducing manual data entry, improving accuracy, and accelerating the submission workflow for pulmonology services and medications.

Does Klivira support re-authorization workflows for chronic pulmonology conditions like severe asthma?

Absolutely. Klivira provides robust support for re-authorization workflows, which are common for chronic pulmonology conditions requiring ongoing biologic therapy. Our system tracks authorization expiry and facilitates the automated preparation and submission of re-authorization requests through Availity, minimizing lapses in care.

Related coverage

Other pulmonology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo